Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Outcome at 7 Years of Age of Former Very Preterm Neonates Treated with Repeated Surfactant for Prolonged Respiratory Distress in the Neonatal Period

Jean-Michel Hascoet
* ,
Hélène Deforge
,
Silvia Demoulin
,
Jean-Charles Picaud
ORCID logo ,
Veronique Zupan
,
Isabelle Ligi
,
Francois Moreau
,
Aurelie Labarre
,
Patrick Daoud
,
Laurent Storme
,
Claude Bonabel
,
Isabelle Hamon
Version 1 : Received: 1 September 2023 / Approved: 4 September 2023 / Online: 5 September 2023 (05:08:28 CEST)

A peer-reviewed article of this Preprint also exists.

Hascoet, J.-M.; Deforge, H.; Demoulin, S.; Picaud, J.-C.; Zupan, V.; Ligi, I.; Moreau, F.; Labarre, A.; Daoud, P.; Storme, L.; Bonabel, C.; Hamon, I. Outcomes at 7 Years of Age of Former Very Preterm Neonates with Repeated Surfactant Treatment for Prolonged Respiratory Distress in the Neonatal Period. J. Clin. Med. 2023, 12, 6220. Hascoet, J.-M.; Deforge, H.; Demoulin, S.; Picaud, J.-C.; Zupan, V.; Ligi, I.; Moreau, F.; Labarre, A.; Daoud, P.; Storme, L.; Bonabel, C.; Hamon, I. Outcomes at 7 Years of Age of Former Very Preterm Neonates with Repeated Surfactant Treatment for Prolonged Respiratory Distress in the Neonatal Period. J. Clin. Med. 2023, 12, 6220.

Abstract

This study aimed evaluating 7 years’ outcome in 118 very preterm newborn (VPN, gestational age=26±1.4wks) involved in a randomized controlled trial. They presented neonatal respiratory distress (RDS) requiring ventilation for 14±2 days post-natal age (PNA). Repeated instillation of 200mg/kg Poractant alfa (SURF) did not improve early bronchopulmonary dysplasia, but SURF infants needed less re-hospitalization than controls for respiratory problem at 1- and 2-years PNA. There was no growth difference at 7.1±0.3 years for 41 SURF vs. 36 controls (80% eligible children); 7.9% SURF vs. 28.6% controls presented asthma (p=0.021). Children underwent cogni-tive assessment (WISC IV) and pulmonary function testing (PFT) measuring spirometry, lung volumes and airway resistance. Spirometry showed differences (p<0.05) between SURF and con-trols (mean±standard deviation (median z-score)) for FEV1 (L/s) (1.188±0.690(-0.803) vs. 1.080±0.243(-1.446)); FEV1 after betamimetics (1.244±0.183(-0.525) vs. 1.091±0.209(-1.342)); FVC (L) (1.402±0.217 (-0.406) vs. 1.265±0.267(-1.141)), and FVC after betamimetics 1.452±0.237 (-0.241) vs. 1.279±0.264(-1.020)). PFT showed no difference in volumes or airway resistance. Global IQ median [Inter-quartile Range] was 89[82:99] vs. 89[76:98] with 61% children >85 in both groups. Former VPN presenting severe neonatal RDS treated with repeated Surfactant have improved lung function and less asthma at 7 years PNA. There were no differences in neurodevelopmental outcome

Keywords

extreme prematurity; surfactant; outcome; children; longitudinal study; pulmonary function testing; neurodevelopment; asthma

Subject

Medicine and Pharmacology, Pediatrics, Perinatology and Child Health

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.